Floatz logo

Cetuximab

Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary

Hummingbird Biosciencemonoclonal_antibodyPhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary cohort.

Asset / SponsorPhaseRating
Carboplatin
Neonc Technologies, Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Oxford
Phase 3BB
Docetaxel
Hummingbird Bioscience
Phase 2BB
Fibrin Sealant
Oxford University Hospitals NHS Trust
Phase 4BB
Eloxatin
University of Oxford
Phase 3BB

View all 50 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →